1. Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E: Potential cure of acute myeloid leukemia: analysis of 1069 consecutive patients in first complete remission. Cancer. 2007, 110: 2756-2760. 10.1002/cncr.23112.
2. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH, ECOG, MRC/NCRI Adult Leukemia Working Party: Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005, 106: 3760-3767. 10.1182/blood-2005-04-1623.
3. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39381), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987, 47: 5846-5852.
4. Tentori L, Graziani G, Gilberti S, Lacal PM, Bonmassar E, D'Atri S: Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia. 1995, 9: 1888-1895.
5. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, Ahmed T: Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol. 2002, 20: 3249-3253. 10.1200/JCO.2002.01.030.